Valeo Pharma's Chairman, Richard MacKay, welcomes Mr. Moghaddam's appointment, anticipating valuable insights from him. Mr. Moghaddam's record of value creation and growth delivery is highly esteemed.
CEO Steve Saviuk expects the restructuring to enable savings and improve decision-making for maximising commercial activities and profitability. New CFO Pascal Tougas is anticipated to enhance Valeo's operational excellence and streamline its activities.
VALEO股票討論區
暫無評論